<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03689608</url>
  </required_header>
  <id_info>
    <org_study_id>R20180319</org_study_id>
    <nct_id>NCT03689608</nct_id>
  </id_info>
  <brief_title>Daily vs Intermittent Restriction of Energy: Controlled Trial to Reduce Diabetes Risk (DIRECT)</brief_title>
  <official_title>Daily vs Intermittent Restriction of Energy: Randomised Controlled Trial to Reduce Diabetes Risk (DIRECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Adelaide</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Salk Institute for Biological Studies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Adelaide</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized trial study, the investigators will compare the glycaemic health benefits
      of intermittent fasting (IF) versus an energy matched daily restriction (DR) approach over
      18-months, and relative to a non-active intervention control (SC) in individuals at risk of
      type 2 diabetes.

      It is hypothesized that IF will result in greater greater improvements in glycaemia control,
      weight loss and improvements in body composition over 18-months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycaemia</measure>
    <time_frame>6 months</time_frame>
    <description>Change in postprandial glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 months</time_frame>
    <description>Change in HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>2 months, 6 months, 18 months</time_frame>
    <description>changes in body weight in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>6 months, 18 months</time_frame>
    <description>changes in body fat mass in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist and hip circumference</measure>
    <time_frame>2 months, 6 months, 18 months</time_frame>
    <description>changes in waist and hip circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood lipids</measure>
    <time_frame>2 months, 6 months, 18 months</time_frame>
    <description>changes in blood lipid profile (total cholesterol, HDL-, LDL-cholesterol and triglycerides)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adherence to intervention</measure>
    <time_frame>2 months, 6 months, 18 months</time_frame>
    <description>assessed by diet records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>2 months, 18 months</time_frame>
    <description>Change in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>2 months, 6 months, 18 months</time_frame>
    <description>Changes in systolic blood pressure and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial glucose</measure>
    <time_frame>18 months</time_frame>
    <description>Change in postprandial glucose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>Intermittent Fasting (IF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 days fasting per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily Restriction (DR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily energy restriction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care (SC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intermittent Fasting (IF)</intervention_name>
    <description>Participants will fast 3 days per week. In fasting days, meal replacements at 30% of daily energy requirements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.</description>
    <arm_group_label>Intermittent Fasting (IF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Daily Restriction (DR)</intervention_name>
    <description>Participants are instructed to restrict energy intake by 30% of daily energy requirements. Meal replacements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.</description>
    <arm_group_label>Daily Restriction (DR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care (SC)</intervention_name>
    <description>Participants will receive current practice guidelines in a static information format, will not take part in any counselling or receive meal replacements.</description>
    <arm_group_label>standard care (SC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  weight-stable (&lt; 5 % fluctuation in their body weight for past 6-months at study
             entry)

          -  score 12 or greater on the AUSDRISK calculator

          -  HbA1c &lt;48 mmol/L (measured at screening)

        Exclusion Criteria:

          -  Personal history/diagnosis (self-reported) of diabetes (type 1 or 2), major
             psychiatric disorders (schizophrenia, major depressive disorder, bipolar disorder,
             eating disorders), gastrointestinal disorders, haematological disorders (i.e.
             thalassemia, iron-deficiency anaemia) insomnia, or any other medical condition, deemed
             unstable by the study physician.

          -  Participants currently taking the following medications will be excluded from
             participating: any medication used to lower blood glucose or antidiabetic medications
             (metformin, sulfonylureas, Glucagon-like peptide-1 GLP-1 analogues [i.e. exenatide],
             thiazolidinediones or DPP-IV inhibitors [i.e. 'gliptins']), medications affecting
             weight, appetite or gut motility (i.e. domperidone, cisapride, orlistat, phentermine,
             topiramate). Participants who are taking stable doses (i.e. &gt; 12 months) of androgenic
             medications (i.e. testosterone) or SSRI's will not be excluded.

          -  weight change in past 3 months (&gt; 5% screening weight)

          -  uncontrolled asthma, current fever, upper respiratory infections

          -  individuals who regularly perform high intensity exercise (&gt;2 week)

          -  current intake of &gt; 140g alcohol/week

          -  current smokers of cigarettes/cigars/marijuana/e-cigarettes/vaporisers

          -  current intake of any recreational drugs

          -  regular blood donor

          -  unable to comprehend study protocol due to English language or cognitive difficulties
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonie Heilbronn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Adelaide</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Hutchison, PhD</last_name>
    <phone>8128 4862</phone>
    <email>amy.hutchison@adelaide.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leonie Heilbronn, PhD</last_name>
    <phone>8128 4838</phone>
    <email>leonie.heilbronn@adelaide.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Adelaide</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonie K Heilbronn, PhD</last_name>
      <phone>+61 8128 4838</phone>
      <email>leonie.heilbronn@adelaide.edu.au</email>
    </contact>
    <investigator>
      <last_name>Leonie K Heilbronn, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Adelaide</investigator_affiliation>
    <investigator_full_name>A/Prof Leonie Heilbronn</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>intermittent fasting</keyword>
  <keyword>calorie restriction</keyword>
  <keyword>prediabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

